Formycon AG (CHIX:FYBD) Beneish M-Score: -2.09 (As of Jun. 26, 2026)


CHIX:FYBD Formycon AG CHIX:FYBD
65 GF Score
Price €63.30
GF Value €115.06
! 5 Warning Signs
View Full Analysis

What is Formycon AG Beneish M-Score?

Formycon AG CHIX:FYBD 65 Beneish M-Score is -2.09 as of Jun. 26, 2026. GuruFocus rates CHIX:FYBD with a GF Score™ of 65/100 and a GF Value™ of €115.06. The stock has 5 warning signs investors should review. Among 831 Biotechnology companies, Formycon AG ranks worse than 59.09% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.09 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Formycon AG's Beneish M-Score or its related term are showing as below:

CHIX:FYBd' s Beneish M-Score Range Over the Past 10 Years
Min: -2.9   Med: -1.95   Max: 2.41
Current: -2.09

During the past 13 years, the highest Beneish M-Score of Formycon AG was 2.41. The lowest was -2.90. And the median was -1.95.


Formycon AG Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Formycon AG's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Formycon AG Beneish M-Score Chart

Formycon AG Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.57 -1.09 -1.35 -2.90 -2.09

Formycon AG Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.35 0.00 -2.90 0.00 -2.09

CHIX:FYBD vs VRTX, REGN, ALNY: Beneish M-Score Comparison

For the Biotechnology subindustry, Formycon AG's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Formycon AG Beneish M-Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Formycon AG's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Formycon AG's Beneish M-Score falls into.


CHIX:FYBD
65GF Score
Formycon AG CHIX:FYBD
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Formycon AG Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Formycon AG for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.6332+0.528 * 2.648+0.404 * 0.9469+0.892 * 0.6383+0.115 * 1.0482
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1.4877+4.679 * -0.102064-0.327 * 1.4963
=-2.09

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec25) TTM:Last Year (Dec24) TTM:
Total Receivables was €32.02 Mil.
Revenue was €44.48 Mil.
Gross Profit was €3.58 Mil.
Total Current Assets was €125.03 Mil.
Total Assets was €739.53 Mil.
Property, Plant and Equipment(Net PPE) was €13.66 Mil.
Depreciation, Depletion and Amortization(DDA) was €86.49 Mil.
Selling, General, & Admin. Expense(SGA) was €20.31 Mil.
Total Current Liabilities was €53.56 Mil.
Long-Term Debt & Capital Lease Obligation was €8.08 Mil.
Net Income was €-64.70 Mil.
Gross Profit was €0.00 Mil.
Cash Flow from Operations was €10.78 Mil.
Total Receivables was €30.71 Mil.
Revenue was €69.67 Mil.
Gross Profit was €14.83 Mil.
Total Current Assets was €95.03 Mil.
Total Assets was €771.72 Mil.
Property, Plant and Equipment(Net PPE) was €14.57 Mil.
Depreciation, Depletion and Amortization(DDA) was €139.07 Mil.
Selling, General, & Admin. Expense(SGA) was €21.39 Mil.
Total Current Liabilities was €33.89 Mil.
Long-Term Debt & Capital Lease Obligation was €9.10 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(32.016 / 44.476) / (30.709 / 69.674)
=0.719849 / 0.440753
=1.6332

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(14.834 / 69.674) / (3.576 / 44.476)
=0.212906 / 0.080403
=2.648

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (125.032 + 13.663) / 739.527) / (1 - (95.025 + 14.57) / 771.715)
=0.812454 / 0.857985
=0.9469

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=44.476 / 69.674
=0.6383

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(139.065 / (139.065 + 14.57)) / (86.487 / (86.487 + 13.663))
=0.905165 / 0.863575
=1.0482

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(20.311 / 44.476) / (21.387 / 69.674)
=0.456673 / 0.306958
=1.4877

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((8.082 + 53.56) / 739.527) / ((9.097 + 33.893) / 771.715)
=0.083353 / 0.055707
=1.4963

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-64.696 - 0 - 10.783) / 739.527
=-0.102064

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Formycon AG has a M-score of -2.09 suggests that the company is unlikely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -2.09 mean?
Formycon AG (CHIX:FYBD) has a Beneish M-Score of -2.09 as of Jun. 26, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Formycon AG and its competitors. According to the industry distribution chart, Formycon AG ranks #491 out of 831 companies in the Biotechnology industry, placing it in the top 59.1%.
Is Formycon AG's Beneish M-Score too high?
Formycon AG's current Beneish M-Score is -2.09. Based on the distribution chart, Formycon AG ranks #491 out of 831 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Formycon AG has a GF Score™ of 65/100, reflecting its overall financial health beyond just this single metric.
How does Formycon AG's Beneish M-Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Formycon AG ranks #491 out of 831 companies for Beneish M-Score. This places Formycon AG in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Biotechnology company?
A good Beneish M-Score depends on the Biotechnology industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Formycon AG and its competitors. Formycon AG's current Beneish M-Score is -2.09. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Formycon AG stock overvalued right now?
Formycon AG (CHIX:FYBD) has a current Beneish M-Score of -2.09. The stock's GF Value™ is €115.06, compared to a current price of €63.30 — trading 45% below its estimated fair value. The current Beneish M-Score is -2.09. Formycon AG's overall GF Score™ is 65/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Formycon AG (CHIX:FYBD), the current Beneish M-Score is -2.09 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Formycon AG (CHIX:FYBD) Overvalued in 2026?

Based on GuruFocus' analysis, Formycon AG stock appears to be undervalued. The current stock price of €63.30 is trading 45% below its estimated GF Value™ of €115.06.

Key valuation signals for CHIX:FYBD:

  • Beneish M-Score: -2.09
  • GF Value™: €115.06 vs. price of €63.30 (45% below fair value)
  • GF Score™: 65/100 with 5 warning signs

No single metric tells the full story. See the CHIX:FYBD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Formycon AG Business Description

Address Fraunhoferstrasse 15, Martinsried, Planegg, BY, DEU, 82152
Formycon AG is an independent developer of high-quality biosimilars, which are follow-on products to biopharmaceutical drugs. The Company focuses on expanding and further developing its scalable biosimilar platform, which includes approved and pipeline products across ophthalmology, immunology, and immuno-oncology. Its key products include FYB201 (ranibizumab), FYB202 (ustekinumab), FYB203 (aflibercept), FYB206 (pembrolizumab), and FYB208 (dupilumab), along with additional biosimilar candidates in various stages of development. The Company generates maximum revenue from Switzerland.
65GF Score

Get the complete analysis for CHIX:FYBD

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€63.30
Price
€115.06
GF Value